New therapeutic strategies for systemic sclerosis - A critical analysis of the literature

Clinical and Developmental Immunology

Volumn 12, Issue 3, 2005, Pages 165-173

  Zandman Goddard, Gisele ^a,b   Tweezer Zaks, Nurit ^a,b   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

ACE inhibitors; Bosentan; Epoprostenol; IVIg; Stem cell transplantation; Systemic sclerosis

Indexed keywords

ACETYLCYSTEINE; ALPHA 1 ANTITRYPSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMMUNOGLOBULIN; LOSARTAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; NITRIC OXIDE; OCTREOTIDE; PENICILLAMINE; PRAZOSIN; PREDNISOLONE; PREDNISONE; PROSTACYCLIN; RECOMBINANT RELAXIN; SILDENAFIL; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; UNIPROST;

ANEMIA; CLINICAL TRIAL; COCHRANE LIBRARY; DIALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE IRRITATION; INTESTINE PSEUDOOBSTRUCTION; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; LUNG ALVEOLITIS; LUNG DISEASE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; METRORRHAGIA; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN TIGHTNESS; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION; KIDNEY DISEASES; PULMONARY FIBROSIS; RAYNAUD DISEASE; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC;

EID: 32144464779     PISSN: 17402522     EISSN: None     Source Type: Journal    
DOI: 10.1080/17402520500233437     Document Type: Review

References (36)

1. Amital H, Rewald E, Levy Y, Bar-Dayan Y, Manthorpe R, Engervall P, et al. 2003. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 62:175-177.
2. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. 2000. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 21(132):425-434.
3. Badesch DB, McLaughlin W, Delcroix M, Vizza CD, Olschewski H, Sitbon O, et al. 2004. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):56S-61S.
4. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 358:1119-1123.
5. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. 1999. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194-1203.
6. D'Angelo S, Cuomo G, Paone C, Colutta E, La Montagna G, Valentini G. 2003. Low-dose intravenous cyclophosphamide in systemic sclerosis: A preliminary safety study. Clin Rheumatol 22:393-396.
7. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC. 1999. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455-461.
8. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. 1999. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646-2655.
9. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. 2004. EBMT/EULAR Registry. Autologous stem cell transplantation in the treatment of systemic sclerosis: Report from the EBMT/EULAR Registry. Ann Rheum Dis 63:974-981.
10. Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C, et al. 2005. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 52:1555-1563.
11. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, et al. 2002. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J. Rheumatol 29:731-736.
12. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. 2002. Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371-2378.
13. Houssiau FA, Vasconcelos C, et al. 2002. D'Cruz D. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121-2131.
14. Lee AJ, Chiao TB, Tsang MP. 2005. Sildenafil for pulmonary hypertension. Ann Pharmacother 39:869-884.
15. Levy Y, Sherer Y, Langevitz P, Lorber M, Rotman P, Fabrizzi F, et al. 2000. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin-a preliminary report. Clin Rheumatol 19:207-211.
16. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, et al. 2004. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum 50:1005-1007.
17. Matsukawa Y, Saito O, Aoki M, Abe M, Nishinarita S, Sawada S, et al. 2002. Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. Prostaglandins Leukot Essent Fatty Acids 67:45-49.
18. McLaughlin W, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. 2005. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25:244-249.
19. Morton SJ, Powell RJ. 2000. Cyclosporin and tacrolimus: Their use in a routine clinical setting for scleroderma. Rheumatology 39:865-869.
20. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, et al. 2000. Inhaled Iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435-443.
21. Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ, et al. 2004. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126:420-427.
22. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. 2002. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298-304.
23. Perlemuter G, Cacoub P, Chaussade S, Wechsler B, Couturier D, Piette JC. 1999. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum 42:1545-1549.
24. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. 2000. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000956.
25. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. 2000. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst.
26. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. 2001. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351-1358.
27. Rosas V, Conte JV, Yang SC, Gaine SP, Borja M, Wigley FM, et al. 2000. Lung transplantation and systemic sclerosis. Ann Transplant 5:38-43.
28. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:1258.
29. Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, et al. 2001. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study. J Rheumatol 28:2257-2262.
30. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al. 2000. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 132:871-879.
31. Sitbon O, Humbert M, et al. 2002. Nuner H.Intravenous infusion of epoprostanol in severe pulmonary hypertension: Long term survival and prognostic factors. J Am Coll Cardiol 40:770-778.
32. Sitbon O, Badesch DB, Channick RN, et al. 2003. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary artery hypertension. A 1-year follow-up study. Chest 124:247-254.
33. Steen VD, Medsger, TA. Jr. 2000. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 133:600-603.
34. Stratton RJ, Wilson H, Black CM. 2001. Pilot study of antithymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40:84-88.
35. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. 2001. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44:1841-1847.
36. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. 2005. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med 171:1292.